News | November 10, 2024
Vimta Labs reports Q2 FY25 PAT at Rs. 17 Cr
Q2 FY25 Total Income was at Rs. 85.4 crore
Q2 FY25 Total Income was at Rs. 85.4 crore
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
SIBUR is developing a special grade of polycarbonate compatible with radiation sterilization
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
The special financing terms offered by United Imaging and structured by Medikabazaar to Krsnaa Diagnostics underscore the strategic importance of this alliance
Subscribe To Our Newsletter & Stay Updated
